Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.61 |
| ▸ | MAPT | P10636 | 3/20 | 0.61 |
| ▸ | LMNA | P02545 | 3/20 | 0.61 |
| ▸ | HPGD | P15428 | 2/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | STS | P08842 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | PPARA | Q07869 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2182381 | 0.94 | ALDH1A1 (0.59) | ALDH1A1SMN1; SMN2MAPTLMNAHPGD | |
| SCHEMBL302512 | 0.92 | ALDH1A1 (0.57) | ALDH1A1SMN1; SMN2MAPTLMNAHPGD | |
| SCHEMBL302663 | 0.92 | ALDH1A1 (0.57) | ALDH1A1SMN1; SMN2MAPTLMNAHPGD | |
| SCHEMBL20211763 | 0.92 | ALDH1A1 (0.57) | ALDH1A1SMN1; SMN2MAPTLMNAHPGD | |
| SCHEMBL2184223 | 0.92 | ALDH1A1 (0.57) | ALDH1A1SMN1; SMN2MAPTLMNAHPGD | |
| SCHEMBL210942 | 0.90 | ALDH1A1 (0.58) | ALDH1A1SMN1; SMN2MAPTLMNAHPGD | |
| SCHEMBL8204708 | 0.87 | ALDH1A1 (0.75) | ALDH1A1SMN1; SMN2MAPTLMNAHPGD | |
| SCHEMBL5090074 | 0.87 | ALDH1A1 (0.75) | ALDH1A1SMN1; SMN2MAPTLMNAHPGD | |
| SCHEMBL8551794 | 0.87 | ALDH1A1 (0.69) | ALDH1A1SMN1; SMN2MAPTLMNAHPGD | |
| SCHEMBL8549614 | 0.85 | ALDH1A1 (0.67) | ALDH1A1SMN1; SMN2MAPTLMNAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111514107-B | Active oxygen response type vesicle and preparation method thereof | 江南大学 | 2021-12-21 | — | — | CN | claimed |
| CN-111514107-A | Active oxygen response type vesicle and preparation method thereof | 江南大学 | 2020-08-11 | — | — | CN | claimed |
| CN-101389631-A | Process for the preparation of porphyrin derivatives as antimicrobial agents by photodynamic therapy (PDT) | DESTINY PHARMA LTD (GB) | 2009-03-18 | — | — | CN | claimed |
| US-20080281091-A1 | Process for the Preparation of Porphyrin Derivatives as Antimicrobial Agents by Photodynamic Therapy (Pdt) | BRUNDISH DEREK | 2008-11-13 | — | — | US | claimed |
| EP-1963333-A1 | PROCESS FOR THE PREPARATION OF PORPHYRIN DERIVATIVES AS ANTIMICROBIAL AGENTS BY PHOTODYNAMIC THERAPY (PDT) | Destiny Pharma Limited (GB) | 2008-09-03 | — | — | EP | claimed |
| WO-2007074340-A1 | PROCESS FOR THE PREPARATION OF PORPHYRIN DERIVATIVES AS ANTIMICROBIAL AGENTS BY PHOTODYNAMIC THERAPY (PDT) | DESTINY PHARMA LIMITED (GB) | 2007-07-05 | — | — | WO | claimed |
| US-12281119-B2 | Imidazo[2,1-f][1,2,4]triazin-4-amine derivatives as TLR7 agonist | BEIGENE, LTD. (KY) | 2025-04-22 | — | — | US | disclosed |
| CN-113454086-B | Imidazo [2,1-F ] [1,2,4] triazin-4-amine derivatives as TLR7 agonists | 百济神州有限公司 | 2025-03-14 | — | — | CN | disclosed |
| EP-3921320-B1 | IMIDAZO [2, 1-F] [1, 2, 4] TRIAZIN-4-AMINE DERIVATIVES AS TLR7 AGONIST | BEIGENE LTD (KY) | 2024-03-06 | — | — | EP | disclosed |
| CN-114507182-B | Fluorescent probe for in-situ monitoring magnesium alloy dynamic corrosion process and preparation and application thereof | 华南理工大学 | 2023-09-26 | — | — | CN | disclosed |
| CN-115433592-A | Salt-tolerant high-foam high-internal phase emulsion stabilizer and preparation method thereof | 江南大学 | 2022-12-06 | — | — | CN | disclosed |
| CN-114507182-A | Fluorescent probe for in-situ monitoring of dynamic corrosion process of magnesium alloy and preparation and application thereof | 华南理工大学 | 2022-05-17 | — | — | CN | disclosed |
| US-20220119394-A1 | IMIDAZO[2,1-F][1,2,4]TRIAZIN-4-AMINE DERIVATIVES AS TLR7 AGONIST | BEONE MEDICINES I GMBH (CH) | 2022-04-21 | — | — | US | disclosed |
| US-6063789-A | Aminoisoquinolines and aminotheinopyridine derivatives and their use as anti-inflammatory agents | ASTRA PHARMACEUTICALS, LTD. (GB) | 2000-05-16 | — | — | US | disclosed |
| US-6028088-A | USEFUL AS ANTIPROLIFERATIVE, ANTIINFLAMMATORY AND ANTIINFECTIVE AGENTS; FOR TREATMENT OF CERTAIN ENDOCRINE DISEASES INCLUDING DIABETES, CERTAIN MALIGNANT AND NON-MALIGNANT PROLIFERATIVE DISEASES INCLUDING PROSTATE CANCER | THE UNIVERSITY OF MISSISSIPPI (US) | 2000-02-22 | — | — | US | disclosed |
| EP-0958294-A1 | 2-(1,2,4-TRIAZOLE-1-YL)-1,3,4-THIADIAZOLE DERIVATIVES HAVING AN EFFECT ON THE C.N.S. AND THE HEART | EGIS GYOGYSZERGYAR (HU) | 1999-11-24 | — | — | EP | disclosed |
| CN-1221407-A | Aminoisoquinolines and aminothienopyridine derivatives and their use as anti-inflammatory agents | ASTRA PHARMA PROD (GB) | 1999-06-30 | — | — | CN | disclosed |
| EP-0892784-A1 | AMINOISOQUINOLINES AND AMINOTHIENOPYRIDINE DERIVATIVES AND THEIR USE AS ANTI-INFLAMMATORY AGENTS | Astra Pharmaceuticals Limited (GB) | 1999-01-27 | — | — | EP | disclosed |
| WO-1998030561-A1 | 2-(1,2,4-TRIAZOLE-1-YL)-1,3,4-THIADIAZOLE DERIVATIVES HAVING AN EFFECT ON THE C.N.S. AND THE HEART | EGIS Gyógyszergyár Rt. (HU) | 1998-07-16 | — | — | WO | disclosed |
| WO-1997038977-A1 | AMINOISOQUINOLINES AND AMINOTHIENOPYRIDINE DERIVATIVES AND THEIR USE AS ANTI-INFLAMMATORY AGENTS | ASTRA PHARMACEUTICALS LTD. (GB) | 1997-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220119394-A1 | IMIDAZO[2,1-F][1,2,4]TRIAZIN-4-AMINE DERIVATIVES AS TLR7 AGONIST | TLR7, TLR1, TLR3 | ALDH1A1 1611/4885SMN1; SMN2 948/4885MAPT 4191/4885 |
| US-12281119-B2 | Imidazo[2,1-f][1,2,4]triazin-4-amine derivatives as TLR7 agonist | TLR7, TLR1, TLR3 | ALDH1A1 1611/4885SMN1; SMN2 948/4885MAPT 4191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.